AKUMS

Akums Drugs & Pharmaceuticals Share Price

₹609.65 +29 (4.99%)

21 Nov, 2024 14:31

SIP TrendupStart SIP in AKUMS

Start SIP

Performance

  • Low
  • ₹610
  • High
  • ₹610
  • 52 Week Low
  • ₹530
  • 52 Week High
  • ₹1,176
  • Open Price₹610
  • Previous Close₹581
  • Volume50,782

Investment Returns

  • Over 1 Month -33.01%
  • Over 3 Month -42.7%
  • Over 6 Month -10.21%
  • Over 1 Year -10.21%
SIP Lightning

Smart Investing Starts Here Start SIP with Akums Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Akums Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 9,596
  • P/B Ratio
  • 13.3
  • Average True Range
  • 37.52
  • EPS
  • 17.41
  • Dividend Yield
  • 0
  • MACD Signal
  • -44.97
  • RSI
  • 22.76
  • MFI
  • 33.25

Akums Drugs & Pharmaceuticals Financials

Akums Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹609.65
+ 29 (4.99%)
pointer
  • stock-down_img
  • Bullish Moving Average 2
  • stock-up_img
  • Bearish Moving Average 9
  • 20 Day
  • ₹740.37
  • 50 Day
  • ₹814.60
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

563.78 Pivot Speed
  • R3 648.12
  • R2 614.38
  • R1 597.52
  • S1 546.92
  • S2 513.18
  • S3 496.32

What's your outlook on Akums Drugs & Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Akums Drugs & Pharmaceuticals Ltd. is India’s leading contract manufacturing company, producing a wide range of pharmaceutical and nutraceutical products. It provides end-to-end solutions, including formulation development, manufacturing, and packaging for domestic and global clients.

Akums Drugs And Pharmaceuticals Ltd has an operating revenue of Rs. 3,966.30 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 4% needs improvement, ROE of 13% is good. The company has a reasonable debt to equity of 16%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 4 which is a POOR score indicating inconsistency in earnings, a RS Rating of 3 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 33 indicates it belongs to a strong industry group of Medical-Products and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Akums Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-09 Quarterly Results
2024-08-24 Quarterly Results

Akums Drugs & Pharmaceuticals F&O

Akums Drugs & Pharmaceuticals Shareholding Pattern

75.26%
5.18%
1.72%
7.34%
2.1%
8.4%

About Akums Drugs & Pharmaceuticals

  • NSE Symbol
  • AKUMS
  • BSE Symbol
  • 544222
  • Managing Director
  • Mr. Sanjeev Jain
  • ISIN
  • INE09XN01023

Similar Stocks to Akums Drugs & Pharmaceuticals

Akums Drugs & Pharmaceuticals FAQs

Akums Drugs & Pharmaceuticals share price is ₹609 As on 21 November, 2024 | 14:17

The Market Cap of Akums Drugs & Pharmaceuticals is ₹9595.5 Cr As on 21 November, 2024 | 14:17

The P/E ratio of Akums Drugs & Pharmaceuticals is As on 21 November, 2024 | 14:17

The PB ratio of Akums Drugs & Pharmaceuticals is 13.3 As on 21 November, 2024 | 14:17

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23